QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:ENTX

Entera Bio (ENTX) Stock Forecast, Price & News

$0.82
+0.01 (+1.24%)
(As of 06/8/2023 ET)
Compare
Today's Range
$0.81
$0.88
50-Day Range
$0.68
$1.16
52-Week Range
$0.47
$2.12
Volume
5,173 shs
Average Volume
158,950 shs
Market Capitalization
$23.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

Entera Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
820.1% Upside
$7.50 Price Target
Short Interest
Healthy
0.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Entera Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$30,300 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.31) to ($0.76) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

530th out of 986 stocks

Biological Products, Except Diagnostic Industry

85th out of 160 stocks


ENTX stock logo

About Entera Bio (NASDAQ:ENTX) Stock

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

Receive ENTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entera Bio and its competitors with MarketBeat's FREE daily newsletter.

ENTX Stock News Headlines

This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
Entera Bio: Q1 Earnings Insights
This Company Is Solving A Multi-Billion Dollar Problem!
This Little Known NASDAQ Stock is Solving a Multi-Billion Dollar Problem!
Entera Bio (NASDAQ:ENTX) Rating Reiterated by HC Wainwright
H.C. Wainwright Sticks to Their Buy Rating for Entera Bio (ENTX)
Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely?
See More Headlines

ENTX Price History

ENTX Company Calendar

Last Earnings
3/31/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTX
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+820.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-13,070,000.00
Net Margins
-9,754.48%
Pretax Margin
-17,171.21%

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.41 per share

Miscellaneous

Free Float
27,321,000
Market Cap
$23.47 million
Optionable
Not Optionable
Beta
1.82

Key Executives

  • Miranda J. Toledano
    Chief Executive Officer & Director
  • Hillel Galitzer
    Chief Operating Officer
  • Dana Yaacov Garbeli
    Chief Financial Officer
  • Gregory Burshtein
    Vice President-Research & Development
  • Anke Hoppe
    Vice President-Clinical Operations













ENTX Stock - Frequently Asked Questions

Should I buy or sell Entera Bio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTX shares.
View ENTX analyst ratings
or view top-rated stocks.

What is Entera Bio's stock price forecast for 2023?

2 brokers have issued twelve-month price targets for Entera Bio's shares. Their ENTX share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 820.1% from the stock's current price.
View analysts price targets for ENTX
or view top-rated stocks among Wall Street analysts.

How have ENTX shares performed in 2023?

Entera Bio's stock was trading at $0.73 at the beginning of the year. Since then, ENTX stock has increased by 11.7% and is now trading at $0.8151.
View the best growth stocks for 2023 here
.

Are investors shorting Entera Bio?

Entera Bio saw a decrease in short interest in May. As of May 15th, there was short interest totaling 37,600 shares, a decrease of 23.7% from the April 30th total of 49,300 shares. Based on an average daily trading volume, of 230,300 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.2% of the shares of the company are sold short.
View Entera Bio's Short Interest
.

When is Entera Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ENTX earnings forecast
.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) released its quarterly earnings data on Friday, March, 31st. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.02. The company earned $0.01 million during the quarter, compared to analyst estimates of $0.10 million. Entera Bio had a negative trailing twelve-month return on equity of 85.95% and a negative net margin of 9,754.48%.

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

When did Entera Bio IPO?

(ENTX) raised $11 million in an initial public offering on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

What is Entera Bio's stock symbol?

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

How do I buy shares of Entera Bio?

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Entera Bio's stock price today?

One share of ENTX stock can currently be purchased for approximately $0.82.

How much money does Entera Bio make?

Entera Bio (NASDAQ:ENTX) has a market capitalization of $23.47 million and generates $130,000.00 in revenue each year. The company earns $-13,070,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How can I contact Entera Bio?

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com.

This page (NASDAQ:ENTX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -